Starling Oncology (STLN) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.13

Estimate

-$0.05

Surprise

-160.0%

Score at report (before → after)

6.3 → 5.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Starling Oncology (STLN) reported a wider loss than forecast — adjusted EPS of -$0.13 against the -$0.05 estimate (a 160.0% shortfall). TrendMatrix's engine moved from Sell (6.3/10) to Hold at 5.9/10 after the report.

• Lake Street Maintains Buy on Starling Oncology, Lowers Price Target to $8 — benzinga, 2026-11-06
• B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10 — benzinga, 2026-11-06
• 12 Health Care Stocks Moving In Friday's Pre-Market Session — benzinga, 2026-11-06

TrendMatrix currently rates STLN Hold at 5.9/10.

2 of the last 4 quarters beat the estimate; this quarter's -160.0% surprise compares with a -18.6% four-quarter average. Next scheduled report: 2027-03-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$3.62

Price target

$8.29

Stop

$3.37

Upside to target

+129.0%

Reward-to-risk

8.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Care Facilities

Market cap

$368.9M

52-week range

$2.32–$7.13

Off 52-week high

49.2%

RSI (14)

26

Volume vs avg

9.76×

Score today

5.9/10